Skip to main content
Top
Published in: Tumor Biology 5/2011

01-10-2011 | Research Article

The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells

Authors: Xue-Qin Li, Dong-Sheng Pei, Guo-Wei Qian, Xiao-Xing Yin, Qian Cheng, Lian-Tao Li, Hui-Zhong Li, Jun-Nian Zheng

Published in: Tumor Biology | Issue 5/2011

Login to get access

Abstract

To investigate the effect of methylated oligonucleotide (MON) targeting Ki-67 promoter on the expression of Ki-67 gene and the proliferation and apoptosis of the human 786-0 renal carcinoma cells, human 786-0 cells were transfected with MON. The activity of Ki-67 promoter was detected by dual-luciferase reporter assay system. Among the five methylated oligonucleotides (MON1–MON5), MON4 is the best excellent one in the inhibition of the Ki-67 promoter activity. The activity of Ki-67 promoter is decreased to 77.88% in 40-nM group, 50.07% in 80-nM group, 35.63% in 120-nM group, 26.09% in 160-nM group, and 16.98% in 200-nM group compared with 0-nM group. The activity of Ki-67 promoter in MON group is decreased to 61.96% at 8 h, 48.93% at 12 h, 15.97% at 24 h, 26.00% at 36 h, 35.01% at 48 h, 46.08% at 72 h, and 66.12% at 96 h compared with pGLBK235 group. These results show that the effect of MON is time- and dose-dependent. The activity of Ki-67 in MON group is decreased to 16.73% compared with pGLBK235 group, while the control groups have no significant difference. The expression of Ki-67 gene in 786-0 cells was detected by RT-PCR and immunohistochemistry, respectively. The expression of Ki-67 mRNA is decreased to 61.04% and that of Ki-67 protein is decreased to 32.07% in MON group compared with the blank group. The proliferation of 786-0 cells was determined by WST-8. The cell proliferation in MON group is decreased to 61.02% at 24 h, 73.78% at 48 h, 79.72% at 72 h, and 91.53% at 96 h compared with the blank group. The cell apoptosis was measured by annexin V and propidium iodide. The number of apoptosis cells in MON group is 2.42 times of that in the blank group at earlier period and 2.57 times at mid-anaphase. We detected the effect of MON on the expression of bax and p53 by Western blot. Compared with the blank group, the expression of bax protein in MON group is increased by 66.12%, while the expression of p53 is decreased to 67.31%. Our study demonstrates that the methylated oligonucleotide targeting Ki-67 promoter has a remarkable effect on the inhibition of Ki-67 expression and the proliferation of the human 786-0 renal carcinoma cells and can induce apoptosis of the 786-0 cells.
Literature
1.
go back to reference Mohammed A, Shergill I, Little B. Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn. 2009;9:75–83.PubMedCrossRef Mohammed A, Shergill I, Little B. Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn. 2009;9:75–83.PubMedCrossRef
2.
go back to reference Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–52.PubMedCrossRef Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–52.PubMedCrossRef
3.
go back to reference Rioux-Leclercq N, Turlin B, Bansard JY, Patard JJ, Manunta A, Moulinoux JP, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501–5.PubMedCrossRef Rioux-Leclercq N, Turlin B, Bansard JY, Patard JJ, Manunta A, Moulinoux JP, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501–5.PubMedCrossRef
4.
go back to reference Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20.PubMedCrossRef Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20.PubMedCrossRef
5.
go back to reference Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.PubMed Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.PubMed
6.
go back to reference MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.PubMedCrossRef MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.PubMedCrossRef
7.
go back to reference Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–7.PubMedCrossRef Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–7.PubMedCrossRef
8.
go back to reference Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer. 2003;105:710–6.PubMedCrossRef Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer. 2003;105:710–6.PubMedCrossRef
9.
go back to reference Zheng JN, Sun YF, Pei DS, Liu JJ, Sun XQ, Chen JC, et al. Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci. 2005;76:1873–81.PubMedCrossRef Zheng JN, Sun YF, Pei DS, Liu JJ, Sun XQ, Chen JC, et al. Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci. 2005;76:1873–81.PubMedCrossRef
10.
go back to reference Zheng JN, Ma TX, Cao JY, Sun XQ, Chen JC, Li W, et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci. 2006;78:724–9.PubMedCrossRef Zheng JN, Ma TX, Cao JY, Sun XQ, Chen JC, Li W, et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci. 2006;78:724–9.PubMedCrossRef
11.
go back to reference Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001;234:10–20.PubMedCrossRef Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001;234:10–20.PubMedCrossRef
12.
13.
go back to reference Hsieh CL. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Mol Cell Biol. 1997;17:5897–904.PubMed Hsieh CL. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Mol Cell Biol. 1997;17:5897–904.PubMed
14.
go back to reference Yao XM, Hu JF, Daniels M, Shiran H, Zhou XJ, Yan HF, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest. 2003;111:265–73.PubMed Yao XM, Hu JF, Daniels M, Shiran H, Zhou XJ, Yan HF, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest. 2003;111:265–73.PubMed
15.
go back to reference Zhai RL, Wang GB, Cai KL. Application of methylated oligonucleotides: a new strategy for gene inactivation. World Chinese Journal of Digestology. 2007;15:3332–7. Zhai RL, Wang GB, Cai KL. Application of methylated oligonucleotides: a new strategy for gene inactivation. World Chinese Journal of Digestology. 2007;15:3332–7.
16.
go back to reference Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50.PubMedCrossRef Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50.PubMedCrossRef
17.
go back to reference Fleming JL, Huang TH, Toland AE. The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res. 2008;68:9116–21.PubMedCrossRef Fleming JL, Huang TH, Toland AE. The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res. 2008;68:9116–21.PubMedCrossRef
19.
go back to reference Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002;99:3740–5.PubMedCrossRef Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002;99:3740–5.PubMedCrossRef
20.
go back to reference Metivier R, Gallais R, Tiffoche C, Peron CL, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature. 2008;452:45–50.PubMedCrossRef Metivier R, Gallais R, Tiffoche C, Peron CL, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature. 2008;452:45–50.PubMedCrossRef
21.
go back to reference Illingworth R, Kerr A, Desousa D, Jorgensen H, Ellis P, Stalker J, et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 2008;6:e22.PubMedCrossRef Illingworth R, Kerr A, Desousa D, Jorgensen H, Ellis P, Stalker J, et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 2008;6:e22.PubMedCrossRef
22.
go back to reference Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99:451–4.PubMedCrossRef Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99:451–4.PubMedCrossRef
23.
go back to reference Ishii T, Fujishiro M, Masuda M, Teramoto S, Matsuse T. A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. Cancer Lett. 2004;212:211–23.PubMedCrossRef Ishii T, Fujishiro M, Masuda M, Teramoto S, Matsuse T. A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. Cancer Lett. 2004;212:211–23.PubMedCrossRef
24.
go back to reference Li HL, Ma AN. Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting survivin gene. Cancer Gene Ther. 2010;17:441–6.PubMedCrossRef Li HL, Ma AN. Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting survivin gene. Cancer Gene Ther. 2010;17:441–6.PubMedCrossRef
25.
go back to reference Ma AN, Huang WL, Wu ZN, Hu JF, Li T, Zhou XJ, et al. Induced epigenetic modifications of the promoter chromatin silence survivin and inhibit tumor growth. Biochem Biophys Res Commun. 2010;393:592–7.PubMedCrossRef Ma AN, Huang WL, Wu ZN, Hu JF, Li T, Zhou XJ, et al. Induced epigenetic modifications of the promoter chromatin silence survivin and inhibit tumor growth. Biochem Biophys Res Commun. 2010;393:592–7.PubMedCrossRef
26.
go back to reference Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakie G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.PubMedCrossRef Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakie G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.PubMedCrossRef
27.
go back to reference Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:894–900.PubMedCrossRef Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:894–900.PubMedCrossRef
28.
go back to reference Endl E, Gerdes J. Posttranslational modifications of the Ki-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol. 2000;182:371–80.PubMedCrossRef Endl E, Gerdes J. Posttranslational modifications of the Ki-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol. 2000;182:371–80.PubMedCrossRef
Metadata
Title
The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells
Authors
Xue-Qin Li
Dong-Sheng Pei
Guo-Wei Qian
Xiao-Xing Yin
Qian Cheng
Lian-Tao Li
Hui-Zhong Li
Jun-Nian Zheng
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0187-0

Other articles of this Issue 5/2011

Tumor Biology 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine